Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
• Transfection host for some immune checkpoint concerning the NFAT signaling pathway
• The discovery of T cell activators by the NFAT signaling bioactivity
• Screen for anti-human CD3xTAA BsAb.
Expression analysis of human CD3 on NFAT (Luc) Jurkat Reporter Cell by FACS.
NFAT (Luc) Jurkat Reporter Cell were stained with APC-R700 labeled Anti-Human CD3 antibody or APC-R700 labeled Isotype antibody.
Activating of NFAT signaling bioactivity by anti-human CD3 antibody (RLU).
This reporter cell was incubated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). The EC50 of anti-human CD3 antibody was approximately 0.078 μg/mL.
Activating of NFAT signaling bioactivity by anti-human CD3 antibody (FOLD).
This reporter cell was incubated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). The max induction fold was approximately 137.
Bioactivity detection of Anti-human CD3xCD19 bispecific antibody.
This reporter cell was incubated with serial dilutions of Blinatumomab (CD3×CD19 BsAb) in the presence of Raji cells that express human CD19 endogenously. The EC50 of Blinatumomab incubated with Raji cells is approximately 0.66 pM with the max induction fold 842.
Passage stability analysis by anti-human CD3 antibody stimulation.
The continuously growing NFAT (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). Anti-human CD3 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 15-34.
Please contact us if you are interested in related cell pool service.
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.
A-Z
